Q.    What does NeoStem do?

A.    We are an international biopharmaceutical company with operations in the U.S. and China. Our business focuses on three key operations: 1) adult stem cell collection and storage services and stem cell therapeutic development in the U.S.; 2) adult stem cell collection and storage services and stem cell-based therapeutic operations in China; 3) generic pharmaceutical operation in China through a majority owned subsidiary. Our Company is committed to advancing the vast therapeutic and diagnostic applications of autologous adult stem cells.

Q.    What is NeoStem’s relationship with Suzhou Erye?

A.    The Company has a 51% controlling  stake in Suzhou Erye. The majority ownership resulted from the Company’s October 2009 acquisition of China Biopharmaceuticals Holding, Inc. (CBH) and Suzhou Erye was CBH’s primary operating subsidiary.

Q.    What is NeoStem’s ticker symbol, exchange and CUSIP?

A.    The Company’s common stock is traded under the ticker symbol NBS on the American Stock Exchange (Amex). The CUSIP for the common stock is 640650305.

Q.    How many common shares does NeoStem have outstanding?

A.    As of March 24, 2010, 43,946,031 shares of the Company’s common stock were outstanding.

Q.    What is NeoStem’s fiscal year?

A.    The Company’s fiscal year ends on December 31.

Q.    Who is NeoStem’s IR contact?

A.    NeoStem, Inc.
Robin Smith, CEO
Phone:    (212) 584-4174
E-mail:    This e-mail address is being protected from spambots. You need JavaScript enabled to view it

CCG Investor Relations, Inc.       
Lei Huang, Account Manager
Phone: (646) 833-3417                                                                     
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Crocker Coulson, President
Phone: (646) 213-1915                                                                                 
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it
       
Q.    Who are NeoStem’s auditor and legal counsel?

A.    The Company’s auditor for fiscal year 2010 is Deloitte & Touche. The Company’s in-house General Counsel is Catherine M. Vaczy, Esq. and external legal counsel is Lowenstein Sandler PC.

Q.    How many employees does NeoStem have?

A.    As of December 31, 2009, we had 25 full-time, and 3 part-time employees in the U.S., and 2 employees in China. Our majority-owned subsidiary Suzhou Erye had 739 employees, of which 536 are full-time employees, in Jiangsu Province, China.

Q.    Who is NeoStem’s transfer agent?

A.    Our transfer agent is Continental Stock Transfer & Trust Company (www.continentalstock.com).